146 related articles for article (PubMed ID: 36683775)
1. Systemic Delivery of a Dual PI3K/mTOR Inhibitor More Effective than Topical Delivery in Preventing Anal Carcinogenesis in an HPV Transgenic Mouse Model.
Gunder LC; Moyer TH; Ziolkowski MR; Keating MK; Leverson GE; Zhang W; Carchman EH
J Cancer Sci Clin Ther; 2022; 6(2):157-173. PubMed ID: 36683775
[TBL] [Abstract][Full Text] [Related]
2. PI3K/mTOR inhibition prevents anal cancer in mice with established low-grade anal dysplasia.
Gunder LC; Moyer TH; Rademacher BL; Auyueng AS; Leverson G; Zhang W; Matkowskyj KA; Carchman EH
Exp Mol Pathol; 2022 Apr; 125():104752. PubMed ID: 35183509
[TBL] [Abstract][Full Text] [Related]
3. Topical application of a dual PI3K/mTOR inhibitor prevents anal carcinogenesis in a human papillomavirus mouse model of anal cancer.
Rademacher BL; Matkowskyj KA; LaCount ED; Carchman EH
Eur J Cancer Prev; 2019 Nov; 28(6):483-491. PubMed ID: 30888976
[TBL] [Abstract][Full Text] [Related]
4. Anal Cancer Prevention Through the Topical Use of Single or Dual PI3K/mTOR Inhibitors.
Gunder LC; Moyer TH; Johnson HR; Auyeung AS; Leverson GE; Zhang W; Matkowskyj KA; Carchman EH
J Surg Res; 2023 Feb; 282():137-146. PubMed ID: 36274448
[TBL] [Abstract][Full Text] [Related]
5. Dysregulation of Autophagy Contributes to Anal Carcinogenesis.
Carchman EH; Matkowskyj KA; Meske L; Lambert PF
PLoS One; 2016; 11(10):e0164273. PubMed ID: 27706233
[TBL] [Abstract][Full Text] [Related]
6. Topical Protease Inhibitor Decreases Anal Carcinogenesis in a Transgenic Mouse Model of HPV Anal Disease.
Gunder LC; Johnson HR; Yao E; Moyer TH; Green HA; Sherer N; Zhang W; Carchman EH
Viruses; 2023 Apr; 15(4):. PubMed ID: 37112993
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Topically Administered Dihydroartemisinin in Treating Papillomavirus-Induced Anogenital Dysplasia in Preclinical Mouse Models.
Gunder LC; Blaine-Sauer S; Johnson HR; Shin MK; Auyeung AS; Zhang W; Leverson GE; Ward-Shaw ET; King RE; McGregor SM; Matkowskyj KA; Lambert PF; Carchman EH
Viruses; 2022 Jul; 14(8):. PubMed ID: 35893697
[TBL] [Abstract][Full Text] [Related]
8. Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth in vitro and in vivo.
Zou Y; Ge M; Wang X
Biochem Biophys Res Commun; 2017 Aug; 490(2):385-392. PubMed ID: 28623128
[TBL] [Abstract][Full Text] [Related]
9. The role of pharmacologic modulation of autophagy on anal cancer development in an HPV mouse model of carcinogenesis.
Rademacher BL; Matkowskyj KA; Meske LM; Romero A; Sleiman H; Carchman EH
Virology; 2017 Jul; 507():82-88. PubMed ID: 28431282
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effects of a combined treatment of PI3K/mTOR dual inhibitor LY3023414 and carboplatin on human endometrial carcinoma.
Jia N; Che X; Jiang Y; Zhu M; Yang T; Feng W
Gynecol Oncol; 2021 Sep; 162(3):788-796. PubMed ID: 34183163
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Models of Anal Cancer Combined-Modality Therapy.
Johnson HR; Gunder LC; Gillette A; Sleiman H; Rademacher BL; Meske LM; Culberson WS; Micka JA; Favreau P; Yao E; Matkowskyj KA; Skala MC; Carchman EH
J Surg Res; 2024 Feb; 294():82-92. PubMed ID: 37864962
[TBL] [Abstract][Full Text] [Related]
12. Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth.
Smith MC; Mader MM; Cook JA; Iversen P; Ajamie R; Perkins E; Bloem L; Yip YY; Barda DA; Waid PP; Zeckner DJ; Young DA; Sanchez-Felix M; Donoho GP; Wacheck V
Mol Cancer Ther; 2016 Oct; 15(10):2344-2356. PubMed ID: 27439478
[TBL] [Abstract][Full Text] [Related]
13. A mouse model for human anal cancer.
Stelzer MK; Pitot HC; Liem A; Schweizer J; Mahoney C; Lambert PF
Cancer Prev Res (Phila); 2010 Dec; 3(12):1534-41. PubMed ID: 20947489
[TBL] [Abstract][Full Text] [Related]
14. Activating Mutations in
Shin MK; Payne S; Bilger A; Matkowskyj KA; Carchman E; Meyer DS; Bentires-Alj M; Deming DA; Lambert PF
Clin Cancer Res; 2019 Mar; 25(6):1889-1900. PubMed ID: 30530704
[TBL] [Abstract][Full Text] [Related]
15. Anal dysplasia screening: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2007; 7(4):1-43. PubMed ID: 23074504
[TBL] [Abstract][Full Text] [Related]
16. Autophagy inhibition sensitizes LY3023414-induced anti-glioma cell activity
Zheng L; Li H; Mo Y; Qi G; Liu B; Zhao J
Oncotarget; 2017 Nov; 8(58):98964-98973. PubMed ID: 29228741
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus oncogene mRNA testing for the detection of anal dysplasia in HIV-positive men who have sex with men.
Silling S; Kreuter A; Hellmich M; Swoboda J; Pfister H; Wieland U
J Clin Virol; 2012 Apr; 53(4):325-31. PubMed ID: 22261122
[TBL] [Abstract][Full Text] [Related]
18. PI3K/mTOR Dual Inhibitor, LY3023414, Demonstrates Potent Antitumor Efficacy Against Esophageal Adenocarcinoma in a Rat Model.
Zaidi AH; Kosovec JE; Matsui D; Omstead AN; Raj M; Rao RR; Biederman RWW; Finley GG; Landreneau RJ; Kelly RJ; Jobe BA
Ann Surg; 2017 Jul; 266(1):91-98. PubMed ID: 27471841
[TBL] [Abstract][Full Text] [Related]
19. A Cross-Sectional Study of the Prevalence of Anal Dysplasia among Women with High-Grade Cervical, Vaginal, and Vulvar Dysplasia or Cancer: The PANDA Study.
Batman S; Messick CA; Milbourne A; Guo M; Munsell MF; Fokom-Domgue J; Salcedo M; Deshmukh A; Dahlstrom KR; Ogburn M; Price A; Fleming ND; Taylor J; Shafer A; Cobb L; Sigel K; Sturgis EM; Chiao EY; Schmeler KM
Cancer Epidemiol Biomarkers Prev; 2022 Dec; 31(12):2185-2191. PubMed ID: 36126275
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of anal dysplasia and HPV genotypes in gynecology patients: The ANGY cross-sectional prospective clinical study protocol.
Pache B; Balaya V; Mathis J; Hübner M; Sahli R; Cavassini M; Sempoux C; Mathevet P; Jacot-Guillarmod M
PLoS One; 2022; 17(10):e0276438. PubMed ID: 36269726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
